2025-08-11T13:28:05-05:00 2025-03-31 390859910 BAKER TILLY ADVISORY GROUP LP 21700 OXNARD ST STE 300 WOODLAND HILLS CA 91367 990 2024-04-01 954002032 THE ALFRED E MANN FOUNDATION FOR SCIENTIFIC RESEARCH ALFR 6617026700 25134 RYE CANYON LOOP SANTA CLARITA CA 91355 ROBERT GREENBERG CEO 6617026700 2025-08-04 1 0 WENDY CAMPOS P00448102 8185771900 2025-08-04 2024 2025-03-06 01:10:19Z HUMANNITY MEDTEC ROBERT GREENBERG 25134 RYE CANYON LOOP SANTA CLARITA CA 91355 57137773 0 X WWW.HUMANNITYMEDTEC.ORG X 1985 CA CONDUCT MEDICAL AND SCIENTIFIC RESEARCH 5 4 137 5 0 0 911 378 233504 420079 41114652 14822058 2798192 2901867 44147259 18144382 6000 10000 0 0 17983031 21161843 0 0 0 13855905 20604681 31844936 41776524 12302323 -23632142 372537856 353361768 6669955 6385007 365867901 346976761 X THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH IS A MEDICAL RESEARCH ORGANIZATION DEDICATED TO DEVELOPING AND COMMERCIALIZING INNOVATIVE SOLUTIONS FOR SIGNIFICANT UNMET MEDICAL CONDITIONS. 0 0 15667719 10000 0 NEUROMODULATION SYSTEMADVANCED IMPLANTABLE NEUROMODULATION SYSTEM DEVELOPMENT:THIS PROGRAM COVERS (A) THE MONITORING AND EVALUATION OF SEVERAL EARLY-STAGE ADVANCED RESEARCH AND DEVELOPMENT EFFORTS UNDERWAY THAT ARE DIRECTED AT DEVELOPING INNOVATIVE TECHNOLOGIES, PROJECT IDEAS AND CONCEPTS BEFORE THEY PROGRESS TO THE STATUS OF FULL-FLEDGED DEVELOPMENT PROGRAMS, AND (B) ONGOING EFFORTS RELATED TO THE ADVANCEMENT OF COMMERCIAL READINESS AND PROTECTION OF RELATED INTELLECTUAL PROPERTY ACROSS THE DEVELOPMENT LIFECYCLE. THE TEAM COMPRISES THE FULL RANGE OF EXPERTISE AVAILABLE AT AMF, INCLUDING EXECUTIVE MANAGEMENT, RESEARCH SCIENTISTS AND ENGINEERS, LEGAL AND INTELLECTUAL PROPERTY EXPERTS, BUSINESS DEVELOPMENT STRATEGISTS AND ANALYSTS.STATUS RESEARCH AND DEVELOPMENT ACTIVITIES ARE UNDERWAY TO ENHANCE THE CAPABILITIES OF A NEUROMODULATION SYSTEM, COMPRISED OF ADVANCED TECHNOLOGIES AND SYSTEM SOLUTIONS IN SUPPORT OF NEW BUSINESS DEVELOPMENT STRATEGIES. 12359601 0 3207233 NEW PROJECT DEVELOPMENTTHIS PROGRAM COVERS (A) THE MONITORING AND EVALUATION OF SEVERAL EARLY STAGE ADVANCED RESEARCH AND DEVELOPMENT EFFORTS UNDERWAY THAT ARE DIRECTED AT DEVELOPING - INNOVATIVE TECHNOLOGIES, PROJECT IDEAS AND CONCEPTS BEFORE THEY PROGRESS TO THE STATUS OF FULL-FLEDGED DEVELOPMENT PROGRAMS, AND (B) ONGOING EFFORTS RELATED TO THE ADVANCEMENT OF COMMERCIAL DEVELOPMENT AND PROTECTION OF INTELLECTUAL PROPERTY OF THESE PROJECTS ACROSS THE DEVELOPMENT LIFECYCLE. THE TEAM COMPRISES THE FULL RANGE OF EXPERTISE AVAILABLE AT AMF, INCLUDING - EXECUTIVE MANAGEMENT, RESEARCH SCIENTISTS AND ENGINEERS, LEGAL AND INTELLECTUAL PROPERTY EXPERTS, BUSINESS DEVELOPMENT STRATEGISTS AND ANALYSTS.EXPENSES MAY INCLUDE ONGOING PARTICIPATION IN THE DEVELOPMENT EFFORT INCLUDING RESEARCH AND DEVELOPMENT SUPPORT, COLLABORATION MANAGEMENT, CONFERENCE AND PROFESSIONAL SOCIETY MEETING ATTENDANCE, SERVICE IN MANAGEMENT OR ON THE BOARD OF DIRECTORS OF SPINOUT ENTITIES, PATENT PROSECUTION AND THE PROSECUTION OF INFRINGEMENT ACTIONS TO PROTECT THE VALUE OF THE INTELLECTUAL PROPERTY WE CREATE. IN ADDITION TO PAYROLL EXPENSES AND DIRECT EXPENSES PAID TO OUTSIDE VENDORS FOR GOODS AND SERVICES RELATED TO PROJECTS, EXPENSES IN THIS PROGRAM MAY INCLUDE TRAVEL EXPENSES, PATENT PROSECUTION EXPENSES AND FEES, LEGAL FEES (FOR INTERNAL AND OUTSIDE LEGAL COUNSEL) FOR EXPENSES TO CREATE, PRESERVE AND PROTECT INTELLECTUAL PROPERTY FROM INFRINGEMENT AND REMEDY PAST INFRINGEMENT, AND INCENTIVE AND OTHER COMPENSATION PAYMENTS TO EMPLOYEES AND OTHERS RELATED TO THESE PROGRAMS AND ACTIONS. IN SOME CASES, CERTAIN OF THESE EXPENDITURES MIGHT BE INCURRED LONG AFTER THE PROJECTS HAVE BEEN LAUNCHED INTO SPINOUT COMPANIES OR LICENSED TO THIRD PARTIES.REVENUES ASSOCIATED WITH THESE PROJECTS (SOME OF WHICH MAY ACCRUE LONG AFTER THE PROJECT AND ANY RELATED PROGRAM HAVE BEEN OUT-LICENSED OR LAUNCHED INTO A SPINOUT COMPANY) MAY INCLUDE RECOVERIES OF JUDGMENTS OR SETTLEMENTS FROM PATENT INFRINGEMENT MATTERS, ROYALTIES ON NET SALES OF LICENSED PRODUCTS, MILESTONE PAYMENTS, ONGOING CONTRACT R&D FROM PARTNERS, LICENSEES AND SPINOUT COMPANIES, INTEREST, AND PROCEEDS OF LIQUIDITY EVENTS (E.G., INITIAL PUBLIC OFFERINGS, ACQUISITIONS) INVOLVING RETAINED EQUITY INTERESTS IN PROJECTS THAT HAVE BEEN SPUN OUT AS STARTUP COMPANIES.STATUS:DESIGN AND DEVELOPMENT ACTIVITIES ARE UNDERWAY FOR A NEW BIOELECTRONIC PROGRAM BASED ON THE BUSINESS CASE ANALYSIS CONDUCTED IN THE PRIOR YEAR. THESE ACTIVITIES INCLUDED GENERATION OF INITIAL SYSTEM REQUIREMENTS, ASSEMBLY OF A TEAM OF KEY OPINION LEADERS WITH DOMAIN EXPERTISE, AND THE INITIATION OF SOME FUNDAMENTAL APPLIED RESEARCH IN THE AREA OF NOVEL ELECTRODE DESIGN, INCLUDING COMPLETION OF PRE-CLINICAL TESTING. ADDITIONALLY, THE BUSINESS DEVELOPMENT TEAM, ALONG WITH EXECUTIVE MANAGEMENT AND OTHER STAFF, PERFORMED PRELIMINARY DUE DILIGENCE ON A NUMBER OF ASSETS. 8273730 0 0 IMPLANTABLE NEUROMODULATION PROJECT #1 TO TREAT CHRONIC DISEASE THE AIM OF THE AMF PROGRAM IS TO DEVELOP A NEUROSTIMULATION SYSTEM THAT WILL IMPROVE MEDICAL OUTCOMES AT A LOWER COST AND/OR HIGHER PATIENT SATISFACTION THAN CURRENTLY AVAILABLE TREATMENT OPTIONS. SUCH A SYSTEM WILL CONSIST OF A FULLY IMPLANTABLE NEURAL STIMULATOR FOR SEAMLESS OPERATION AND REQUIRING MINIMAL INTERACTION FROM A PATIENT, WITH THE GOAL OF OFFERING A HIGHER LEVEL OF PATIENT SATISFACTION, ADOPTION, AND COMPLIANCE.STATUS:FINAL DESIGN VERIFICATION TESTING ACTIVITIES OF THE IMPLANTABLE DEVICE AND EXTERNALS ARE UNDERWAY IN SUPPORT OF A FIRST-IN-HUMAN STUDY. DESIGN AND MANUFACTURING IMPROVEMENTS HAVE BEEN MADE; PRE-CLINICAL ANIMAL STUDIES WERE COMPLETED. 153300 0 0 IMPLANTABLE NEUROMODULATION PROJECT #2: - TO TREAT A RANGE OF NEUROLOGICAL CONDITIONS. THE SYSTEM WILL CONSIST OF AN IMPLANTABLE NEURAL STIMULATOR AND EXTERNALS DESIGNED TO MAXIMIZE THERAPY OUTCOMES AND PATIENT SATISFACTION WHILE MINIMIZING SYSTEM COSTS.STATUS:PLANNING, DESIGN, AND DEVELOPMENT OF THE FIRST IN-HUMAN IMPLANT AND EXTERNALS IS UNDERWAY; FEASIBILITY PLANNING AND INITIATIVES INCLUDE PRE-CLINICAL STUDIES AND COMPUTATIONAL MODELING OF TARGETED NEURAL STRUCTURES. 68860 0 108505 IMPLANTABLE DRUG PUMP (IDP)THE IDP IS A SOPHISTICATED, HIGHLY PROGRAMMABLE DRUG INFUSION DEVICE THAT IS IMPLANTED IN THE BODY AND REFILLED VIA A HYPODERMIC NEEDLE THROUGH THE SKIN. INFUSION RATES AND SCHEDULES MAY BE PROGRAMMED, AND VIA VARIOUS FORMS OF CATHETERS, DRUGS CAN BE DELIVERED INTRATHECALLY TO THE SPINAL COLUMN, INTO THE ABDOMEN, INTO THE BRAIN, OR INTRAVENOUSLY. STATUS: AMF HAS SOLD THE IDP TECHNOLOGY TO A STRATEGIC PARTNER THAT IS AN INTERNATIONAL MEDICAL DEVICE COMPANY. AMF CONTINUES TO SUPPORT THE STRATEGIC PARTNER AS IT WORKS TO ADAPT THE DESIGN FOR DIABETES BY DELIVERING INSULIN TO THE ABDOMEN AND READY IT FOR COMMERCIALIZATION FOR THE BENEFIT OF PATIENTS WITH HARD-TO-TREAT TYPE 1 DIABETES. FIRST-IN-HUMAN IMPLANTATION HAS BEEN ACCOMPLISHED. 40018 0 0 IMPLANTABLE NEUROMODULATION PROJECT #2 - TO TREAT A RANGE OF NEUROLOGICAL CONDITIONS. THE SYSTEM WILL CONSIST OF AN IMPLANTABLE NEURAL STIMULATOR AND EXTERNALS DESIGNED TO MAXIMIZE THERAPY OUTCOMES AND PATIENT SATISFACTION WHILE MINIMIZING SYSTEM COSTS.STATUS PLANNING, DESIGN, AND DEVELOPMENT OF THE FIRST-IN-HUMAN IMPLANT AND EXTERNALS IS UNDERWAY; FEASIBILITY PLANNING AND INITIATIVES INCLUDE PRE-CLINICAL STUDIES AND COMPUTATIONAL MODELING OF TARGETED NEURAL STRUCTURES. 1652 3008 IMPLANTABLE MYOELECTRIC SENSOR II (IMES INFINITY)THE TECHNOLOGY HAS BEEN LICENSED TO A STRATEGIC PARTNER THAT IS AN INTERNATIONAL MEDICAL DEVICE COMPANY.STATUS:ADDITIONAL ANALYSIS AND DEVELOPMENT WORK WAS DONE TO PREDICT FEASIBILITY OF THE USE OF THE DEVICE ON LOWER LIMBS; DESIGN TRANSFER SUPPORT ACTIVITIES WERE ALSO CONDUCTED. 263830 0 111513 36564880 1 0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 39 0 1 137 1 0 0 0 0 0 0 0 0 0 0 1 0 X 5 4 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 CA X FARAH BOROOMAND 6617026731 25134 RYE CANYON LOOP SANTA CLARITA CA 91355 ROBERT GREENBERG CEO/PRESIDENT/CHAIR OF THE BOARD 44.00 X X 1176449 0 145692 KEN WEATHERWAX BOARD MEMBER 1.25 X 0 0 0 RICHARD WAUGH BOARD MEMBER 1.50 X 0 0 0 DAVID GILL BOARD MEMBER 1.50 X 0 0 0 HEATHER PAGE BOARD MEMBER 1.25 X 0 0 0 FARAH BOROOMAND CHIEF FINANCIAL OFFICER/TREASURER 44.00 X 510007 0 64791 COREY DISHMON CHIEF BUSINESS AND LEGAL OFFICER 40.00 X 404186 0 23740 PHILIP LEE SECRETARY/ASSISTANT GENERAL COUNSEL 40.00 X 216632 0 39503 JOHN RIVERA VICE PRESIDENT, PRODUCT DEVELOPMENT 41.00 X 357505 0 32174 CEDRIC NAVARRO V.P. QUALITY ASSURANCE, REG. AFFAIRS, INTERIM 40.00 X 283665 0 53331 NEIL TALBOT VP, RESEARCH AND TECHNOLOGY 42.00 X 321393 0 39729 SHAWN LEWIS VICE PRESIDENT, HUMAN RESOURCES 40.00 X 318397 0 39172 BRIAN MECH VP, STRATEGY 40.00 X 306807 0 9977 VALMA KLEIN VP, CLINICAL AFFAIRS 41.00 X 274441 0 32066 CARL BUICE SENIOR DIRECTOR, PROJECT MANAGEMENT 40.00 X 280991 0 43754 4450473 0 523929 68 0 1 0 MORGAN LEWIS & BOCKIUS LLP 1701 MARKET STREET PHILADELPHIA PA 19103 LEGAL SERVICES 3758302 STUART KARTEN DESIGN (DBA KARTEN DESIGN 4204 GLENCOE AVENUE MARINA DEL REY CA 90292 R&D CONSULTANTS 595720 MEDIX STAFFING SOLUTIONS INC 222 S RIVERSIDE PLAZA SUITE 2120 CHICAGO IL 60606 SOFTWARE CONSULTANTS 396451 LEWIS ROCA ROTHGERBER CHRISTIE LLP 201 EAST WASHINGTON STREET PHOENIX AZ 85004 LEGAL SERVICES (PATENTS) 320656 UBS INVESTMENT MANAGEMENT 299 PARK AVENUE NEW YORK NY 10171 INVESTMENT MANAGEMENT FEES 309937 19 378 378 NEW PROJECTS 541700 308566 308566 IMPLANTABLE DRUG PUMP (IDP) 541700 108505 108505 IMPLANTABLE MYOELECTRIC SENSOR II 541700 3008 3008 420079 9596093 9596093 2702674 2702674 44217403 1953 38991272 2119 5226131 -166 5225965 5225965 LEGAL FEES REFUND 900099 195993 195993 OTHER INCOME 900099 3200 3200 199193 18144382 3318746 0 14825258 10000 10000 3548367 2674495 873872 14327511 12630345 1697166 432526 380911 51615 1714746 1555851 158895 1138693 1006689 132004 8828960 8590486 238474 115214 115214 1212875 1212875 4091132 3976059 115073 2380710 2263341 117369 620616 607753 12863 1425033 1253956 171077 216771 182477 34294 113737 82603 31134 1119337 1026186 93151 142702 126321 16381 EMPLOYEE MORALE 178110 157028 21082 RECRUITING EXP & RELOCA 108688 2000 106688 EMPLOYEE TRAINING 34914 25113 9801 MEALS 15882 13266 2616 41776524 36564880 5211644 0 3936641 602819 116082439 88774317 1225 0 258166 296888 12150428 7680759 3255116 4469669 195028530 194030607 49977919 61869909 1004764 1062425 2993056 2255134 372537856 353361768 3970204 4289806 2699751 2095201 6669955 6385007 X 365867901 346976761 365867901 346976761 372537856 353361768 -23632142 4741002 0 X 0 1 X 1 0 X UCLA FOUNDATION LOS ANGELES CA 1538026 1133713 404313 8927831 5118076 3809755 1684571 1428970 255601 4469669 HEDGE FUNDS INTERNATIONAL 59867760 F LIMITED PARTNERSHIPS 91420 F OTHER INVESTMENTS 1910729 F 61869909 OPERATING LEASE LIABILITIES 2095201 2095201 X 22885384 4741002 4741002 18144382 0 18144382 41776524 0 41776524 0 41776524 PART X, LINE 2: THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH IS EXEMPT FROM FEDERAL INCOME AND CALIFORNIA FRANCHISE TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND THE CORRESPONDING CALIFORNIA PROVISIONS. THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH HAD NO SIGNIFICANT UNRELATED BUSINESS INCOME TAX DURING THE YEAR ENDED MARCH 31, 2025. ACCORDINGLY, NO TAX PROVISION FOR UNRELATED BUSINESS INCOME HAS BEEN MADE IN THE ACCOMPANYING FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024 AND 2025. THE FOUNDATION, UNDER THE PROVISIONS OF ASC 740, INCOME TAXES, HAD NO UNCERTAIN TAX POSITIONS REQUIRING ACCRUAL AS OF MARCH 31, 2024 AND 2025. CENTRAL AMERICA AND THE CARIBBEAN 0 0 INVESTMENTS 28807085 NORTH AMERICA 0 0 INVESTMENTS 3150 SOUTH ASIA 0 1 PROGRAM SERVICES R&D SOFTWARE SERVICES 323509 EUROPE (INCLUDING ICELAND & GREENLAND) 0 2 PROGRAM SERVICES SOFTWARE SERVICES 78081 CENTRAL AMERICA AND THE CARIBBEAN 0 1 PROGRAM SERVICES CLINICAL RESEARCH 321 NORTH AMERICA 0 0 PROGRAM SERVICES SOFTWARE SERVICES 111700 0 4 0 0 0 4 29323846 0 29323846 1 0 1 1 1 0 PART I, LINE 3: THE ACCRUAL METHOD OF ACCOUNTING IS USED FOR BOTH AMOUNTS REPORTED AS INVESTMENTS AND EXPENDITURES. X 1 1 X X X 0 0 0 1 0 0 0 1 0 ROBERT GREENBERG CEO/PRESIDENT/CHAIR OF THE BOARD 586299 0 590150 0 0 0 10350 0 135342 0 1322141 0 0 0 FARAH BOROOMAND CHIEF FINANCIAL OFFICER/TREASURER 323038 0 186969 0 0 0 9277 0 55514 0 574798 0 0 0 COREY DISHMON CHIEF BUSINESS AND LEGAL OFFICER 329036 0 75150 0 0 0 9163 0 14577 0 427926 0 0 0 JOHN RIVERA VICE PRESIDENT, PRODUCT DEVELOPMENT 297355 0 60150 0 0 0 10350 0 21824 0 389679 0 0 0 NEIL TALBOT VP, RESEARCH AND TECHNOLOGY 264743 0 56650 0 0 0 7905 0 31824 0 361122 0 0 0 SHAWN LEWIS VICE PRESIDENT, HUMAN RESOURCES 277247 0 41150 0 0 0 8819 0 30353 0 357569 0 0 0 CEDRIC NAVARRO V.P. QUALITY ASSURANCE, REG. AFFAIRS 248665 0 35000 0 0 0 6255 0 47076 0 336996 0 0 0 CARL BUICE SENIOR DIRECTOR, PROJECT MANAGEMENT 243841 0 37150 0 0 0 8740 0 35014 0 324745 0 0 0 BRIAN MECH VP, STRATEGY 277507 0 29300 0 0 0 8594 0 1383 0 316784 0 0 0 VALMA KLEIN VP, CLINICAL AFFAIRS 210791 0 63650 0 0 0 6649 0 25417 0 306507 0 0 0 PHILIP LEE SECRETARY/ASSISTANT GENERAL COUNSEL 190982 0 25650 0 0 0 5809 0 33694 0 256135 0 0 0 PART I, LINE 1A THERE WAS ONE FIRST-CLASS TICKET IN CALENDAR YEAR 2024. THIS BENEFIT WAS EXCLUDED FROM TAXABLE COMPENSATION BECAUSE THERE WAS NO OTHER SUITABLE TICKET AVAILABLE AT THE TIME OF BOOKING AND THE REQUIRED APPROVAL WAS OBTAINED PER COMPANY POLICY. PART I, LINE 5 AWARDS WERE PAID THIS YEAR UNDER TWO INCENTIVE COMPENSATION PLANS: A) THE ALFRED MANN FOUNDATION FOR SCIENTIFIC RESEARCH INCENTIVE COMPENSATION PLAN AND B) THE DEFERRED COMPENSATION PLAN. THE INCENTIVE PLAN WILL CONTINUE UPON THE RECEIPT BY AMF OF QUARTERLY ROYALTIES UNDER A LICENSE AGREEMENT COVERING CERTAIN AMF PATENTS AND OTHER INTELLECTUAL PROPERTY LICENSED. PAYMENT OF THE CURRENT DEFERRED COMP INCENTIVE WILL CONTINUE FOR ONE MORE YEAR. THE PURPOSE OF THESE PLANS IS TO ENHANCE THE ABILITY OF AMF TO ATTRACT AND RETAIN HIGHLY QUALIFIED EMPLOYEES BY PROVIDING INCENTIVE COMPENSATION OPPORTUNITIES. TO THE EXTENT THE PLANS PROVIDE FOR A DEFERRAL OF COMPENSATION, THE PLANS ARE INTENDED TO BE INELIGIBLE DEFERRED COMPENSATION PLANS WITHIN THE MEANING OF SECTION 457(F) OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE "CODE"). EMPLOYEES DESIGNATED TO RECEIVE AWARDS ENTER INTO AN INDIVIDUAL AWARD AGREEMENTS UNDER THE PLAN. PLAN AWARDS PROVIDE DEFERRED INCENTIVE COMPENSATION TO AWARD RECIPIENTS ARE INTENDED TO SERVE AS A GENERAL EMPLOYEE RETENTION TOOL, - AS WELL AS A REWARD FOR KEY PARTICIPANTS IN THE UNDERLYING PROJECT OR RESEARCH EFFORT THAT WAS THE SUBJECT OF SUCH PLAN. UPON ACTUAL RECEIPT BY AMF OF PROCEEDS OF A LIQUIDITY EVENT (AND AFTER DEDUCTING CERTAIN AMOUNTS DESIGNED TO REIMBURSE AMF FOR ITS COSTS OF THE UNDERLYING ASSET), AN AWARD POOL IS CREATED AND AWARD RECIPIENTS ARE PAID A PERCENTAGE OF THE NET PROCEEDS RECEIVED BY AMF. TYPICALLY, THE TOTAL AWARDS TO ALL RECIPIENTS IN ANY PLAN DO NOT EXCEED 15.00% OF THE AMOUNT OF NET PROCEEDS REALIZED BY AMF. NO AMOUNTS ARE PAYABLE UNLESS AND UNTIL AMF HAS ACTUALLY RECEIVED THE PROCEEDS OF A LIQUIDITY EVENT OR ROYALTIES UNDER THE LICENSE AGREEMENT. THE AWARDS ARE SUBJECT TO SEVERAL CONDITIONS, DESIGNED TO PROVIDE A SUBSTANTIAL RISK OF FORFEITURE TO THE AWARD RECIPIENT. THERE ARE ALSO CAPS TO THE PAYMENT OF AWARDS UNDER THE AWARD AGREEMENT. - RESTRICTIONS SET FORTH IN EACH AWARD AGREEMENT LIMIT THE MAXIMUM AMOUNT OF PROCEEDS TO WHICH A RECIPIENT'S AWARD PERCENTAGE OR FIXED AMOUNT WILL APPLY. THE PLANS AND ALLOCATIONS WERE APPROVED BY THE BOARD OF DIRECTORS AFTER REVIEWING DETAILED COMPENSATION ANALYSIS INFORMATION PREPARED BY AN INDEPENDENT NATIONAL FIRM AND RECEIVING OUTSIDE LEGAL ADVICE, BOTH RELATING TO THE REASONABLENESS OF THE AWARD COMPENSATION. THE PLANS EQUIRE THAT THIS COMPENSATION ANALYSIS BE UPDATED AT LEAST EVERY TWO YEARS. PART I, LINE 7 BONUSES ARE PAID PURSUANT TO: #1, "THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH ANNUAL INCENTIVE PLAN AND #2, "THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH KEY CONTRIBUTOR AWARD PROGRAM". BOTH PLANS ARE RENEWED AND APPROVED EACH YEAR BY THE BOARD OF DIRECTORS. "THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH ANNUAL INCENTIVE PLAN" IS BASED ON THE ACHIEVEMENT OF PERSONAL AND CORPORATE GOALS, AMONG OTHER CONSIDERATIONS, WHILE "THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH KEY CONTRIBUTOR AWARD PROGRAM" IS DESIGNED TO PROVIDE FOR PERFORMANCE AND RETENTION INCENTIVES BASED ON INDIVIDUAL AND FOUNDATION-WIDE PERFORMANCE TO ELIGIBLE EMPLOYEES OF THE FOUNDATION. FORM 990, PART VI, SECTION B, LINE 11B A DRAFT OF THE 990 WILL BE PRESENTED BY MANAGEMENT TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR THEIR REVIEW AND DISCUSSION. A FULL COPY OF THE FORM WILL BE PROVIDED TO ALL VOTING MEMBERS PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST DISCLOSURES ARE UPDATED ANNUALLY AND POTENTIAL CONFLICTS ARE REVIEWED PRIOR TO PARTICIPATING IN TRANSACTIONS. IF A CONFLICT EXISTS, THE PERSON WITH A CONFLICT DOES NOT VOTE. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE COMPENSATION OF THE CEO AND HIS DIRECT REPORTS INCLUDING THE CFO. IT ALSO REVIEWS AND APPROVES THE OVERALL ANNUAL ADJUSTMENTS TO COMPENSATION OF OTHER EMPLOYEES. SPECIFIC ADJUSTMENTS FOR OTHER EMPLOYEES ARE HANDLED BY THE CEO AND HEAD OF HUMAN RESOURCES USING COMPARISONS TO SALARY SURVEYS FOR SIMILAR POSITIONS AND EXPERIENCE. THE BOARD OF DIRECTORS APPROVED COMPENSATION FOR THE CEO AND HIS DIRECT REPORTS INCLUDING THE CFO ON 3/13/2025. THIS PROCESS WAS DOCUMENTED AND USED DETAILED INFORMATION AND ANALYSIS FROM AN INDEPENDENT NATIONAL EXECUTIVE COMPENSATION ANALYSIS FIRM. FORM 990, PART VI, SECTION C, LINE 19 MEMBERS OF THE PUBLIC OR INTERESTED PARTIES MAY REQUEST TO REVIEW OR RECIEVE A COPY OF THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS BY PHONE OR MAIL.